Pareto and Analysguiden publish research reports with SEK 25 per share price targets and ExpreS2ion publishes third quarter financial report video presentation
Hørsholm, Denmark, November 18, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in November. Pareto reiterated its SEK 25 price target while Analysguiden reduced its price target to SEK 25 per share from SEK 30 per share. Furthermore, a filmed company presentation by CEO Bent U. Frandsen and CFO Keith Alexander, hosted by H.C. Andersen Capital, in which they provide an update on ExpreS2ion’s powerful technology platform for vaccine development, pipeline projects, and interim financial results for the first nine months of 2022, is now available on the company’s website.
The Analysguiden report provides a thorough assessment of the COVID-19 vaccine candidate ABNCoV2 including an evaluation of recent developments in the marketplace for COVID-19 vaccines and data for competing vaccines. It also includes a sum-of-the-parts analysis for estimating fair value per share and prospective financial estimates. Analysguiden’s new price target of SEK 25 per share is based on the sum-of-the-parts valuation analysis, with upside to SEK 50 per share should a bull case for the COVID-19 vaccine be realized.
The research reports are available on the Analyst Reports page of ExpreS2ion’s investor website.
A recording of the presentation of the interim financial results for the first nine months of 2022 and the presentation materials are available on the Presentations page of ExpreS2ion’s investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.